文献速递细菌感染、耐药与抗菌药物艾滋病与性传播感染

Gepotidacin对多重耐药淋病奈瑟菌临床分离株的体外活性

In vitro activity of gepotidacin against a challenging panel of multidrug-resistant Neisseria gonorrhoeae isolates.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

该研究评估了新型拓扑异构酶抑制剂Gepotidacin对2015至2023年英国卫生安全局收集的23株头孢曲松耐药淋病奈瑟菌的体外活性,琼脂稀释法显示96%的菌株在≤2 mg/L时被抑制,MIC50和MIC90分别为0.5和2 mg/L。所有菌株均携带与环丙沙星耐药相关的氨基酸改变及MtrCDE外排泵过表达突变,但Gepotidacin活性似乎不受这些耐药机制影响。

要点

  • Gepotidacin对头孢曲松耐药淋球菌体外活性良好,96%菌株MIC≤2 mg/L。
  • 常见氟喹诺酮耐药突变和外排泵过表达未明显影响Gepotidacin的体外活性。
  • 罕见的GyrA A92P改变经结构分析不影响Gepotidacin结合。

核心结论

  • Gepotidacin对头孢曲松耐药淋球菌临床分离株具有体外活性,其活性似乎不受本组菌株耐药机制影响。

研究设计与样本

  • 对2015至2023年英国卫生安全局收到的23株头孢曲松耐药(MIC≥0.25 mg/L)淋病奈瑟菌临床分离株进行琼脂稀释法药敏试验,并分析基因组耐药决定因素和序列型。

主要发现

  • Gepotidacin抑制96%的分离株在≤2 mg/L,MIC范围0.25-4 mg/L,MIC50为0.5 mg/L,MIC90为2 mg/L。
  • 全部23株菌均存在与环丙沙星耐药相关的氨基酸改变,其中10株携带罕见的GyrA A92P改变,但认为不影响Gepotidacin结合。
  • 全部菌株均有导致MtrCDE外排泵过表达的突变,10株有导致NorM外排泵过表达的突变。
  • 共鉴定9种MLST,细分为16种NG-MAST和14种NG-STAR型,最常见MLST为ST8123,其对Gepotidacin的MIC范围与总体分布相似。

临床怎么用

  • 对于头孢曲松耐药的淋病奈瑟菌感染,Gepotidacin可能是一个有前景的治疗选择,但需临床研究进一步验证。

局限性

  • 本研究为体外研究,样本量仅23株,且仅针对头孢曲松耐药菌株,不能直接推断临床疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Gepotidacin is a novel triazaacenaphthylene topoisomerase inhibitor that has demonstrated non-inferiority to 500 mg of intramuscular ceftriaxone plus 1 g of oral azithromycin for the treatment of uncomplicated urogenital gonorrhoea. We evaluated gepotidacin in vitro activity against a panel of ceftriaxone-resistant Neisseria gonorrhoeae isolates that were referred to the UK Health Security Agency between 2015 and 2023. METHODS: Gepotidacin and comparator antimicrobials were tested against 23 ceftriaxone-resistant (MIC ≥0.25 mg/L) N. gonorrhoeae isolates by agar dilution. Genomic sequences were examined for known resistance determinants and sequence types. RESULTS: Gepotidacin inhibited the majority (96%) of isolates at ≤2 mg/L, with MIC range, MIC50 and MIC90 values of 0.25-4, 0.5 and 2 mg/L, respectively. All 23 isolates had amino-acid modifications associated with ciprofloxacin resistance, including the rare GyrA A92P alteration in 10 isolates, none of which are believed to effect gepotidacin binding. All isolates had mutations causing the overexpression of the MtrCDE efflux pump and 10 isolates had mutations causing the overexpression of the NorM efflux pump. Nine different MLSTs were subdivided into 16 and 14 NG-MAST and NG-STAR types, respectively. MLST ST8123 was the most prevalent MLST and the gepotidacin MIC range against this sequence type was similar to the overall distribution. CONCLUSION: Overall, gepotidacin was active in vitro against this challenging panel of ceftriaxone-resistant gonococcal clinical isolates. Gepotidacin activity does not seem to be affected in this ceftriaxone-resistant set of strains. A structural analysis suggests that the rare GyrA A92P alteration identified in this study does not affect gepotidacin binding.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Cole MJ, Doumith M, Vickers A, et al. In vitro activity of gepotidacin against a challenging panel of multidrug-resistant Neisseria gonorrhoeae isolates. J Antimicrob Chemother. 2026. PMID: 41574658. doi:10.1093/jac/dkag001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。